Champions Oncology, INC 10-K annual reports

Champions Oncology, Inc. announced its fiscal year 2026 results, reporting a 4.4% increase in revenue to $59.4 million, driven by growth in pharmacology services, despite a net loss for the year.

Champions Oncology, a technology-enabled research organization, announced a significant financial turnaround in fiscal year 2025, achieving net income and positive cash flow from operations driven by increased revenue from research services and new data licensing.

Champions Oncology's annual report reveals a net loss of $7.3 million for fiscal year 2024 and raises substantial doubt about the company's ability to continue as a going concern.